Registration number: 06815590

CHOPRAS PHARMACY LIMITED

Contents

Company Information	1
Balance Sheet	2 to 3
Notes to the Unaudited Financial Statements	4 to 9

CHOPRAS PHARMACY LIMITED

Company Information

Director

Mr Sunil Chopra

Company secretary

Mrs Sushma Chopra

Registered office

6 Main Road Hextable Swanley Kent BR8 7RA

Accountants

Bharat Shah & Co Chartered Accountants 786 London Road Thornton Heath Surrey CR7 6JB

CHOPRAS PHARMACY LIMITED

(Registration number: 06815590)
Balance Sheet as at 31 March 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	5	70,141	73,876
Other financial assets	6	771,515	771,515
		841,656	845,391
Current assets
Stocks	7	76,500	85,515
Debtors	8	934,769	976,147
Cash at bank and in hand		66,136	54,451
		1,077,405	1,116,113
Creditors: Amounts falling due within one year	9	(266,360)	(305,123)
Net current assets		811,045	810,990
Total assets less current liabilities		1,652,701	1,656,381
Creditors: Amounts falling due after more than one year	9	(9,706)	(32,382)
Provisions for liabilities		(17,480)	(18,401)
Net assets		1,625,515	1,605,598
Capital and reserves
Called up share capital		100	100
Retained earnings		1,625,415	1,605,498
Shareholders' funds		1,625,515	1,605,598

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

CHOPRAS PHARMACY LIMITED

(Registration number: 06815590)
Balance Sheet as at 31 March 2025

Approved and authorised by the director on 30 December 2025
 

......................................... Mr Sunil Chopra Director

CHOPRAS PHARMACY LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1	General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
6 Main Road
Hextable
Swanley Kent
BR8 7RA

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

CHOPRAS PHARMACY LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Leasehold improvements	20% Reducing Balance
Fixtures and Equipments	5% Reducing Balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

CHOPRAS PHARMACY LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3	Staff numbers

The average number of persons employed by the company (including the director) during the year, was 10 (2024 - 10).

CHOPRAS PHARMACY LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4	Profit before tax

Arrived at after charging/(crediting)

	2025 £	2024 £
Depreciation expense	3,735	3,942

CHOPRAS PHARMACY LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

5	Tangible assets

	Land and buildings £	Furniture, fittings and equipment  £	Total £
Cost or valuation
At 1 April 2024	7,774	145,529	153,303
At 31 March 2025	7,774	145,529	153,303
Depreciation
At 1 April 2024	7,500	71,927	79,427
Charge for the year	55	3,680	3,735
At 31 March 2025	7,555	75,607	83,162
Carrying amount
At 31 March 2025	219	69,922	70,141
At 31 March 2024	274	73,602	73,876

6	Other financial assets (current and non-current)

	Financial assets at fair value through profit and loss £	Total £
Non-current financial assets
Cost or valuation
At 1 April 2024	771,515	771,515
At 31 March 2025	771,515	771,515
Impairment
Carrying amount
At 31 March 2025	771,515	771,515

7

Stocks

	2025 £	2024 £
Other inventories	76,500	85,515

CHOPRAS PHARMACY LIMITED

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

8

Debtors

Current	2025 £	2024 £
Trade debtors	96,662	108,369
Prepayments	12,099	11,679
Other debtors	826,008	856,099
	934,769	976,147

9

Creditors

Creditors: amounts falling due within one year

	Note	2025 £	2024 £
Due within one year
Loans and borrowings	10	21,958	21,107
Trade creditors		145,427	192,858
Taxation and social security		8,489	15,153
Accruals and deferred income		87,415	75,686
Other creditors		3,071	319
		266,360	305,123

Creditors: amounts falling due after more than one year

	Note	2025 £	2024 £
Due after one year
Loans and borrowings	10	9,706	32,382

10	Loans and borrowings

Non-current loans and borrowings

	2025 £	2024 £
Bank borrowings	9,706	32,382

Current loans and borrowings

	2025 £	2024 £
Bank borrowings	21,958	21,107